PRasugrel hydrochloride 是一种噻吩吡啶和前药，是一种可口服的P2Y12受体拮抗剂，抑制 ADP 诱导的血小板聚集，用于预防急性冠状动脉综合征患者的血栓形成、不稳定型心绞痛和心肌梗塞，以及接受经皮冠状动脉介入治疗的患者。

Prasugrel hydrochloride is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.

Prasugrel significantly inhibits arterio-venous (AV) shunt and electrically induced arterial thrombosis in single dose ranges of 0.3 to 3 mg/kg and of 0.3 and 1 mg/kg/day for multiple doses. These doses are similar to doses with inhibition of platelet activation via P2Y12 receptors, suggesting that the protective effects of prasugrel in these cerebral infarction and peripheral arterial occlusive disease models reflect P2Y12 inhibitions on platelets by prasugrel's active metabolite. Prasugrel also significantly prevents progression of peripheral vascular lesions[1].

389574-19-0

C20H21ClFNO3S

409.9

Prasugrel HCl;PCR 4099 (hydrochloride);盐酸普拉格雷;Effient Hydrochloride;LY 640315 Hydrochloride;LY 640315

Ethanol:9 mg/mL (21.95 mM)
H2O:<1 mgml
DMSO:43 mg/mL (104.9 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years